Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, will release its Q2 2025 financial results on Thursday, August 14, 2025 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, will release its Q2 2025 financial results on Thursday, August 14, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET/1:30 PM PT to discuss the results and provide a business update.
Investors can access the webcast through Talphera's website investor section, which will include a slide presentation. A replay will be available for 90 days. For those joining by phone, North American callers can dial 1-800-836-8184, while international callers should use 1-646-357-8785 with conference ID 32530.
[]Details
News Market Reaction – TLPH
On Aug 8, the first trading day after this news, TLPH closed 4.60% above the previous close.
Data tracked by StockTitan Argus for the Aug 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast Information
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-second-quarter-financial-results-and-corporate-update-call-and-webcast-on-thursday-august-14-2025-302524765.html
SOURCE Talphera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.